|
[1]
|
Wang, P.-X., Wang, H.-J., Liu, J.-H., et al. (2021) A Nomogram Combining Plasma Fibrinogen and Systemic Im-mune-Inflammation Index Predicts Survival in Patients with Resectable Gastric Cancer. Scientific Reports, 11, Article No. 10301. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Choi, Y.Y., Noh, S.H. and Cheong, J.H. (2016) Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. Journal of Pathology and Translational Medicine, 50, 1-9. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Rodriquenz, M.G., Roviello, G., D’Angelo, A., et al. (2020) MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy. Journal of Clinical Medicine, 9, 1427. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Martinez-Ciarpaglini, C., Fleitas-Kanonnikoff, T., Gambardella, V., et al. (2019) Assessing Molecular Subtypes of Gastric Cancer: Microsatellite Unstable and Epstein-Barr Virus Subtypes. Methods for Detection and Clinical and Pathological Implications. Science for Optimal Cancer Care, 4, e000470. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Joshi, S.S. and Badgwell, B.D. (2021) Current Treatment and Recent Progress in Gastric Cancer. CA: A Cancer Journal for Clinicians, 71, 264-279. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Puliga, E., Corso, S., Pietrantonio, F., et al. (2021) Microsatellite Instability in Gastric Cancer: Between Lights and Shadows. Cancer Treatment Reviews, 95, Article ID: 102175. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Chao, J., Fuchs, C.S., Shitara, K., et al. (2021) Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncology, 7, 895-902. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Luchini, C., Bibeau, F., Ligtenberg, M.J.L., et al. (2019) ESMO Recommendations on Microsatellite Instability Testing for Immunotherapy in Cancer, and Its Relationship with PD-1/PD-L1 Expression and Tumour Mutational Burden: A Systematic Review-Based Approach. Annals of On-cology, 30, 1232-1243. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Pietrantonio, F., Miceli, R., Raimondi, A., et al. (2019) Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability as a Biomarker in Gastric Cancer. Journal of Clinical Oncology, 37, 3392-3400. [Google Scholar] [CrossRef]
|
|
[11]
|
Smyth, E.C., Wotherspoon, A., Peckitt, C., et al. (2017) Mismatch Re-pair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adju-vant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncology, 3, 1197-1203. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Pietrantonio, F., Randon, G., Di Bartolomeo, M., et al. (2021) Predictive Role of Microsatellite Instability for of PD-1 Blockade in Patients with Advanced Gastric Cancer: A Me-ta-Analysis of Randomized Clinical Trials. Science for Optimal Cancer Care, 6, Article ID: 100036. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Roudko, V., Bozkus, C.C., Orfanelli, T., et al. (2020) Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. Cell, 183, 1634-1649.e17. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Fontana, E. and Smyth, E.C. (2021) Dissecting Response and Re-sistance to Anti-PD-1 Therapy in Microsatellite-Unstable Gastric Cancer. Cancer Discovery, 11, 2126-2128. [Google Scholar] [CrossRef]
|